Kobeissi Hassan, Ghozy Sherief, Flood Richard, Mortimer Alex, Crossley Robert, Cox Anthony, Minks David, Wareham James
Department of Radiology, 6915Mayo Clinic, Rochester, MN, USA.
College of Medicine, 5649Central Michigan University, Mt Pleasant, MI, USA.
Interv Neuroradiol. 2023 Apr 4:15910199231167915. doi: 10.1177/15910199231167915.
The MIVI Q aspiration catheters have been shown to achieve significantly greater flow rates than other intracranial aspiration catheters in vitro. We describe our initial real-world experience with the MIVI Q catheter in emergent acute ischemic stroke (AIS) caused by distal and medium vessel occlusions (DMVO).
Data was collated from a prospectively maintained database which included patients from October 2019 to December 2022. Occlusion demographics, thrombectomy technique, reperfusion scoring, procedural complications and disposition were assessed. The primary outcome of interest was rate of successful reperfusion defined as thrombolysis in cerebral infarction (TICI) score 2b-3. Secondary outcomes included rate of first pass effect (FPE) and complications.
We included 64 target occlusions in 51 patients. The Q catheter successfully reached the DMVO in all occlusions. Successful reperfusion was achieved in 49/64 (76.6%) occlusions, and TICI scores were similar for primary and secondary DMVOs (P value = 0.41). FPE was achieved in 39/64 (60.9%) occlusions and did not differ between primary and secondary DMVOs (P value = 0.13). Reperfusion hemorrhage occurred in 3/64 (4.7%) cases, small volume subarachnoid hemorrhage in 3/64 (4.7%) cases, and small hemorrhagic transformation in 1/64 (1.6%) cases; the rate of complications did not differ based on primary versus secondary DMVO (P value = 0.29).
The MIVI Q catheter is both safe and effective. Our real-world experience supports the superior flow rates demonstrated in vitro and translates into high rates of successful reperfusion in AIS caused by DMVO in clinical practice.
在体外实验中,MIVI Q抽吸导管的血流速度显著高于其他颅内抽吸导管。我们描述了在由远端和中间血管闭塞(DMVO)引起的急性缺血性卒中(AIS)急诊中使用MIVI Q导管的初步实际应用经验。
数据来自一个前瞻性维护的数据库,该数据库纳入了2019年10月至2022年12月的患者。评估了闭塞的人口统计学特征、取栓技术、再灌注评分、手术并发症和处置情况。主要关注的结局是成功再灌注率,定义为脑梗死溶栓(TICI)评分2b - 3。次要结局包括首次通过效应(FPE)率和并发症。
我们纳入了51例患者的64处目标闭塞。Q导管在所有闭塞中均成功到达DMVO。49/64(76.6%)处闭塞实现了成功再灌注,原发性和继发性DMVO的TICI评分相似(P值 = 0.41)。39/64(60.9%)处闭塞实现了FPE,原发性和继发性DMVO之间无差异(P值 = 0.13)。3/64(4.7%)例发生再灌注出血,3/64(4.7%)例发生少量蛛网膜下腔出血,1/64(1.6%)例发生少量出血性转化;基于原发性与继发性DMVO的并发症发生率无差异(P值 = 0.29)。
MIVI Q导管安全有效。我们的实际应用经验支持了体外实验中所显示的优越血流速度,并在临床实践中转化为DMVO所致AIS的高成功再灌注率。